These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 28272134)

  • 1. Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations.
    Winckelmann A; Barton K; Hiener B; Schlub TE; Shao W; Rasmussen TA; Østergaard L; Søgaard OS; Tolstrup M; Palmer S
    AIDS; 2017 Mar; 31(6):771-779. PubMed ID: 28272134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals.
    Winckelmann A; Morcilla V; Shao W; Schleimann MH; Hojen JF; Schlub TE; Denton PW; Østergaard L; Søgaard OS; Tolstrup M; Palmer S
    AIDS; 2018 Aug; 32(13):1793-1802. PubMed ID: 29762162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial.
    Leth S; Schleimann MH; Nissen SK; Højen JF; Olesen R; Graversen ME; Jørgensen S; Kjær AS; Denton PW; Mørk A; Sommerfelt MA; Krogsgaard K; Østergaard L; Rasmussen TA; Tolstrup M; Søgaard OS
    Lancet HIV; 2016 Oct; 3(10):e463-72. PubMed ID: 27658863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individuals.
    Moron-Lopez S; Kim P; Søgaard OS; Tolstrup M; Wong JK; Yukl SA
    AIDS; 2019 Mar; 33(3):425-431. PubMed ID: 30531314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of concordance between residual viremia and viral variants driving de novo infection of CD4(+) T cells on ART.
    Puertas MC; Noguera-Julian M; Massanella M; Pou C; Buzon MJ; Clotet B; Stevenson M; Paredes R; Blanco J; Martinez-Picado J
    Retrovirology; 2016 Aug; 13(1):51. PubMed ID: 27484989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Diversity, Compartmentalization, and Age of HIV Proviruses Persisting in CD4
    Jones BR; Miller RL; Kinloch NN; Tsai O; Rigsby H; Sudderuddin H; Shahid A; Ganase B; Brumme CJ; Harris M; Poon AFY; Brockman MA; Fromentin R; Chomont N; Joy JB; Brumme ZL
    J Virol; 2020 Feb; 94(5):. PubMed ID: 31776273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-molecule techniques to quantify and genetically characterise persistent HIV.
    Wang XQ; Palmer S
    Retrovirology; 2018 Jan; 15(1):3. PubMed ID: 29316955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.
    Søgaard OS; Graversen ME; Leth S; Olesen R; Brinkmann CR; Nissen SK; Kjaer AS; Schleimann MH; Denton PW; Hey-Cunningham WJ; Koelsch KK; Pantaleo G; Krogsgaard K; Sommerfelt M; Fromentin R; Chomont N; Rasmussen TA; Østergaard L; Tolstrup M
    PLoS Pathog; 2015 Sep; 11(9):e1005142. PubMed ID: 26379282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells.
    Bailey JR; Sedaghat AR; Kieffer T; Brennan T; Lee PK; Wind-Rotolo M; Haggerty CM; Kamireddi AR; Liu Y; Lee J; Persaud D; Gallant JE; Cofrancesco J; Quinn TC; Wilke CO; Ray SC; Siliciano JD; Nettles RE; Siliciano RF
    J Virol; 2006 Jul; 80(13):6441-57. PubMed ID: 16775332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Antiretroviral Therapy Duration on HIV-1 Infection of T Cells within Anatomic Sites.
    Lee E; von Stockenstrom S; Morcilla V; Odevall L; Hiener B; Shao W; Hartogensis W; Bacchetti P; Milush J; Liegler T; Sinclair E; Hatano H; Hoh R; Somsouk M; Hunt P; Boritz E; Douek D; Fromentin R; Chomont N; Deeks SG; Hecht FM; Palmer S
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31723024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.
    Mohey R; Jørgensen LB; Møller BK; Black FT; Kjems J; Obel N
    J Clin Virol; 2005 Dec; 34(4):257-67. PubMed ID: 16286049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV Proviral Burden, Genetic Diversity, and Dynamics in Viremic Controllers Who Subsequently Initiated Suppressive Antiretroviral Therapy.
    Omondi FH; Sudderuddin H; Shahid A; Kinloch NN; Jones BR; Miller RL; Tsai O; MacMillan D; Trocha A; Brockman MA; Brumme CJ; Joy JB; Liang R; Walker BD; Brumme ZL
    mBio; 2021 Dec; 12(6):e0249021. PubMed ID: 34781741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dual-target approach in viral HIV-1 viremia testing: An added value to virological monitoring?
    Amendola A; Sberna G; Forbici F; Abbate I; Lorenzini P; Pinnetti C; Antinori A; Capobianchi MR
    PLoS One; 2020; 15(2):e0228192. PubMed ID: 32023284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy.
    Kearney MF; Wiegand A; Shao W; Coffin JM; Mellors JW; Lederman M; Gandhi RT; Keele BF; Li JZ
    J Virol; 2016 Feb; 90(3):1369-76. PubMed ID: 26581989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-resistance mutations number and K70R or T215Y/F substitutions predict treatment resumption during guided treatment interruptions.
    Darwich L; Esteve A; Ruiz L; Paredes R; Bellido R; Cabrera C; Romeu J; Bofill M; Clotet B; Martinez-Picado J
    AIDS Res Hum Retroviruses; 2008 May; 24(5):725-32. PubMed ID: 18462084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 latent reservoir size and diversity are stable following brief treatment interruption.
    Salantes DB; Zheng Y; Mampe F; Srivastava T; Beg S; Lai J; Li JZ; Tressler RL; Koup RA; Hoxie J; Abdel-Mohsen M; Sherrill-Mix S; McCormick K; Overton ET; Bushman FD; Learn GH; Siliciano RF; Siliciano JM; Tebas P; Bar KJ
    J Clin Invest; 2018 Jul; 128(7):3102-3115. PubMed ID: 29911997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV migration between blood plasma and cellular subsets before and after HIV therapy.
    Choi JY; Chaillon A; Oh JO; Ahn JY; Ann HW; Jung IY; Ahn MY; Jeon YD; Ku NS; Smith DM; Kim JM
    J Med Virol; 2016 Apr; 88(4):606-13. PubMed ID: 26348372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy.
    Brennan TP; Woods JO; Sedaghat AR; Siliciano JD; Siliciano RF; Wilke CO
    J Virol; 2009 Sep; 83(17):8470-81. PubMed ID: 19535437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of proviral copy number and plasma RNA level as early indicators of progression in HIV-1 infection: correlation with virological and immunological markers of disease.
    Verhofstede C; Reniers S; Van Wanzeele F; Plum J
    AIDS; 1994 Oct; 8(10):1421-7. PubMed ID: 7529507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.